A Phase 2/3 interventional study of Intravenous S. aureus phage cocktail and Placebo in Staphylococcal Aureus Infection, sponsored by University of Melbourne. Not yet recruiting at 11 sites in Australia. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by University of Melbourne · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a domain of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial.
The SNAP Trial is an International Multi-Centered Randomised Adaptive Platform Clinical Trial to evaluate a range of interventions for patients with Staphylococcus Aureus bacteraemia (SAB). The SNAP Trial clinicaltrials.gov listing is NCT05137119.
The University of Melbourne is the Global Coordinating Centre for the SNAP Trial; each participating region will have their own sponsor who will maintain responsibility for trial activities in their region.
The primary objective is to evaluate the impact of adjunctive phage therapy in clearing the bloodstream infection in SAB.
Secondary objectives are to determine:
305 studies on the registry are indexed under Staphylococcal Infections; 36 are open to participants now.
This study's planned enrollment of 270 is above the median of 124 across 199 interventional studies indexed under Staphylococcal Infections.
Browse Staphylococcal Infections studies →University of Melbourne is the lead sponsor of 87 studies on the registry; 23 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1mL of 1x 1010 plaque forming units (PFU) of each phage will be administered intravenously (IV), twice a day for 5 days (10 doses). Both phages will be supplied to hospital pharmacies in separate vials. 1mL of each phage will be drawn from supplied vials and both added to a bag of 50mL (or 100mL) of 0.9% normal saline and administered IV over 10-15 minutes (or up to 30 minutes if a slower infusion is required).
Drug: Intravenous S. aureus phage cocktail
52mL (or 102mL) administered IV, twice a day for 5 days (10 doses) over 10-15 minutes (or up to 30 minutes if a slower infusion is required). Study medication should be made up in the pharmacy in normal saline as close to the timing of administration as possible.
Other: Placebo
JIPh\_Sau300 and JIPh\_Sau301
Intravenous normal \[0.9%\] saline
Positive blood culture 44-76 hours after domain entry
At least one positive blood culture collected 44-76 hours after domain entry.
Time frame: From domain entry until 46-76 hours after domain entry
Duration of bacteraemia
Defined as days from domain entry until date of collection of the first negative blood culture for S. aureus, censored at platform day 14
Time frame: From domain entry, censored at platform day 14
In vitro resistance against one or more of the phages
In vitro resistance against one or more of the phages included in the intervention that occurs in the final S. aureus isolate obtained from a blood culture from a participant in the phage therapy arm only (not placebo arm), where the index blood culture from the participant at platform entry demonstrated susceptibility to the same phage.
Time frame: Platform day 90
Serum neutralisation (antiphage antibody) against one or more of the phages
Serum neutralisation (antiphage antibody) against one or more of the phages included in the intervention, that was not present on a blood sample collected at domain entry, and that develops on any serum sample obtained from domain entry until the end of platform day 14 or until total discharge (censored at day 31), whichever occurs last, in a participant in the active phage therapy arm and in around 10% of participants in the placebo arm, selected randomly. Total discharge is defined as the timepoint when the participant has 1) Ended their initial hospital admission to any acute inpatient facility, including HITH/OPAT/COPAT and stepdown inpatient rehabilitation/post-acute care (if continuous with the initial admission to a SNAP-enrolling hospital) AND 2) Ended their IV antibiotic treatment for SAB
Time frame: From domain entry until the end of platform day 14 or until total discharge (censored at day 31), whichever occurs last
Serious Adverse Events (SAEs)
SAEs that occur from domain entry until the end of platform day 14.
Time frame: From platform entry until day 14
At least one occurrence of a clinically significant change (worsening)
At least one occurrence of a clinically significant change (worsening) in 2 or more of heart rate (HR), respiratory rate (RR), temperature, blood pressure (BP) from a pre-dose baseline, occurring up to 12 hours following any dose of study medication, as assessed by a treating clinician.
Time frame: From platfrom entry until day 90
LFT Derangement
LTF derangement defined as: 1. Grade 2 or above increase in ALT and/or GGT (\>2.5x ULN), which was not present on any blood sample collected within 24 hours of domain entry occurring from platform day 5 (+/-1 day) until the end of platform day 14 or until acute discharge, whichever occurs first; or 2. \>2.5x increase in enzyme levels in those with abnormal results at (or within 24 hours of) domain entry, occurring from platform day 5 (+/-1 day) until the end of platform day 14 or until acute discharge, whichever occurs first. or 3. If ALT and GGT are unknown at (or within 24 hours of) domain entry, ≥5x ULN in ALT and/or GGT occurring from platform day 5 (+/-1 day) until the end of platform day 14 or until acute discharge, whichever occurs first. Acute discharge is defined as the timepoint when the participant has ended their hospital admission at an acute inpatient facility, at either the primary site or secondary acute care site (if continuous with the initial admission).
Time frame: From domain entry until day 90 or acute discharge, whichever occurs first
Core Secondary Endpoint: All-cause mortality 90 days after platform entry
Only specified core protocol outcomes (listed in NCT05137119) apply to this domain as secondary endpoints.
Time frame: From platform entry until day 90
Core Secondary Endpoint: All-cause mortality 28 days after platform entry
Only specified core protocol outcomes (listed in NCT05137119) apply to this domain as secondary endpoints.
Time frame: From platform entry until day 28
Core Secondary Endpoint: All-cause mortality 42 days after platform entry
Only specified core protocol outcomes (listed in NCT05137119) apply to this domain as secondary endpoints.
Time frame: From platform entry until day 42
Core Secondary Endpoint: Time to being discharged alive from the total index hospitalisation (including HITH/COPAT/OPAT/rehab)
Only specified core protocol outcomes (listed in NCT05137119) apply to this domain as secondary endpoints.
Time frame: From platform entry to total discharge, truncated at 90 days
Core Secondary Endpoint: Serious adverse reactions possibly, probably or definitely attributable to an intervention in the phage domain
Only specified core protocol outcomes (listed in NCT05137119) apply to this domain as secondary endpoints.
Time frame: From platform entry until day 90
Plan to share: Yes — All requests for data sharing must be accompanied by a SNAP data access request from, a study proposal with clear statement of aims and hypotheses, and a statistical analysis plan. All applications will be assessed by the SNAP Trial Steering Committee. Applications from investigators with suitable academic capability to conduct the proposed work will be given consideration. If a proposal is approved, a signed data transfer agreement will be required before data sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Time frame: IPD and supporting information will be available 12 months after the publication of the primary results manuscript and will be available for a 10 year period.
Data sharing details ↗ · www.snaptrial.com.au
Start is estimated for Dec 2026; primary completion for Dec 2029, 36 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Melbourne